IOVA
NEUTRAL
$3.7
Live
Iovance Biotherapeutics, Inc. · NASDAQ
Target $9.0
(+143.2%)
$1.64
52W Range
$5.63
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 12, 2026
Market cap
$1.52B
P/E
N/A
ROE
-55.5%
Profit margin
-148.4%
Debt/Equity
0.07
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
75%
IOVA presents a classic high-risk, high-reward biotechnology profile, characterized by a stable Piotroski F-Score of 4/9 and a lack of traditional valuation metrics like the Graham Number due to negative earnings. While the company maintains a strong liquidity position with a current ratio of 3.20 and very low debt (D/E 0.07), it suffers from severe profitability issues with a profit margin of -148.38%. The stark contrast between the bearish technical trend (0/100) and the aggressive analyst target price of $9.00 suggests a speculative environment where fundamental health is secondary to future growth expectations.
Key Strengths
Strong liquidity with a Current Ratio of 3.20 and Quick Ratio of 2.74
Very low leverage with a Debt/Equity ratio of 0.07
Positive Gross Margin (34.28%) indicating viable core product pricing
Consistent revenue growth (17.70% YoY)
Strong analyst consensus with a target price ($9.00) significantly above current market price
Key Risks
Extreme negative profitability (Profit Margin -148.38%)
Severe long-term price erosion (5Y Change -87.4%)
Bearish technical trend and recent 1-month price decline of 23.6%
High Price/Sales ratio (5.78) relative to current earnings capacity
Dependence on future commercialization to reverse negative ROE (-55.50%)
AI Fair Value Estimate
Based on comprehensive analysis
$6.35
+71.6% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
37
Weak
30
70
20
65
0
AI Verdict
Speculative Hold
Key drivers: Strong balance sheet liquidity, Deep operational losses, High analyst optimism vs. poor technicals
Confidence
80%
Value
30/100
Valuation is based on future potential rather than current fundamentals.
Positives
- Price/Book is relatively moderate at 2.18
Watchpoints
- Negative P/E
- High Price/Sales ratio
- No Graham Number available due to lack of earnings
Future
70/100
Growth metrics are positive, but the path to profitability is not yet clear.
Positives
- YoY Revenue growth of 17.70%
- Improving EPS growth (+30.8% YoY)
- High analyst target price
Watchpoints
- Forward P/E remains negative
Past
20/100
Historical performance is heavily bearish.
Positives
- Recent 6-month recovery (+76.2%)
Watchpoints
- Catastrophic 5-year return (-87.4%)
- Consistent history of earnings misses
Health
65/100
Balance sheet is healthy, but operational efficiency is poor.
Positives
- Piotroski F-Score of 4/9 (Stable)
- Very low Debt/Equity
- Excellent current and quick ratios
Watchpoints
- Negative ROE and ROA
Dividend
0/100
Typical for growth-stage biotech.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.7
Analyst Target
$9.0
Upside/Downside
+143.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for IOVA and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
IOVA
Iovance Biotherapeutics, Inc.
Primary
|
-87.4% | -32.7% | +20.9% | +76.2% | -23.6% | +7.9% |
|
AXGN
Axogen, Inc.
Peer
|
+76.4% | +203.1% | +75.6% | +145.6% | +0.6% | +5.8% |
|
IMCR
Immunocore Holdings plc
Peer
|
-3.6% | -38.5% | +20.3% | -4.2% | -4.5% | +0.7% |
|
GENB
Generate Biomedicines, Inc.
Peer
|
-8.8% | -8.8% | -8.8% | -8.8% | -5.6% | -16.1% |
|
ANIP
ANI Pharmaceuticals, Inc.
Peer
|
+113.5% | +73.9% | +14.7% | -27.9% | -7.5% | -4.8% |
IOV
Iovance Biotherapeutics, Inc.
Primary
5Y
-87.4%
3Y
-32.7%
1Y
+20.9%
6M
+76.2%
1M
-23.6%
1W
+7.9%
AXG
Axogen, Inc.
Peer
5Y
+76.4%
3Y
+203.1%
1Y
+75.6%
6M
+145.6%
1M
+0.6%
1W
+5.8%
IMC
Immunocore Holdings plc
Peer
5Y
-3.6%
3Y
-38.5%
1Y
+20.3%
6M
-4.2%
1M
-4.5%
1W
+0.7%
GEN
Generate Biomedicines, Inc.
Peer
5Y
-8.8%
3Y
-8.8%
1Y
-8.8%
6M
-8.8%
1M
-5.6%
1W
-16.1%
ANI
ANI Pharmaceuticals, Inc.
Peer
5Y
+113.5%
3Y
+73.9%
1Y
+14.7%
6M
-27.9%
1M
-7.5%
1W
-4.8%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-15.63
PEG Ratio
N/A
P/B Ratio
2.18
P/S Ratio
5.78
EV/Revenue
4.84
EV/EBITDA
-3.52
Market Cap
$1.52B
Profitability
Profit margins and return metrics
Profit Margin
-148.38%
Operating Margin
-84.66%
Gross Margin
34.28%
ROE
-55.5%
ROA
-27.3%
Growth
Revenue and earnings growth rates
Revenue Growth
+17.7%
Earnings Growth
N/A
Q/Q Revenue Growth
+17.74%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.07
Low debt
Current Ratio
3.2
Strong
Quick Ratio
2.74
Excellent
Cash/Share
$0.72
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.1B
Gross Margin
50.3%
Op. Margin
-84.7%
Net Margin
-82.9%
Total Assets
$0.9B
Liabilities
$0.2B
Equity
$0.7B
Debt/Equity
0.31x
Operating CF
$-0.1B
CapEx
$-0.0B
Free Cash Flow
$-0.1B
FCF Yield
118%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-02-24
$-0.18
-0.9% surprise
2025-11-06
$-0.25
+2.9% surprise
2025-08-07
$-0.33
-19.4% surprise
Healthcare Sector Comparison
Comparing IOVA against 264 companies in the Healthcare sector
(20 bullish, 87 neutral, 157 bearish)
Return on Equity (ROE)
-55.5%
This Stock
vs
-46.09%
Sector Avg
+20.4%
(Excellent)
Profit Margin
-148.38%
This Stock
vs
-19.58%
Sector Avg
+657.6%
(Superior)
Debt to Equity
0.07
This Stock
vs
4.1
Sector Avg
-98.3%
(Less Debt)
Revenue Growth
17.7%
This Stock
vs
88.16%
Sector Avg
-79.9%
(Slower)
Current Ratio
3.2
This Stock
vs
3.58
Sector Avg
-10.6%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
IOVA
Iovance Biotherapeutics, Inc.
|
NEUTRAL | $1.52B | - | -55.5% | -148.4% | $3.7 | |
|
AXGN
Axogen, Inc.
|
NEUTRAL | $1.51B | - | -1.9% | -1.0% | $32.83 | Compare |
|
IMCR
Immunocore Holdings plc
|
BEARISH | $1.57B | - | -9.6% | -8.9% | $31.05 | Compare |
|
GENB
Generate Biomedicines, Inc.
|
BEARISH | $1.47B | - | -81.7% | -% | $11.53 | Compare |
|
ANIP
ANI Pharmaceuticals, Inc.
|
BEARISH | $1.58B | 21.23 | 16.2% | 8.9% | $70.49 | Compare |
IOVA
Iovance...
NEUTRAL
Mkt Cap
$1.5B
P/E
-
ROE
-55.5%
Price
$3.7
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-05 | BILINSKY IGOR P | Chief Operating Officer | Stock Award | 31,246 | - |
| 2026-03-05 | VOGT FREDERICK G | Chief Executive Officer | Stock Award | 62,493 | - |
| 2026-03-05 | GRAF FINCKENSTEIN FRIEDRICH | Officer | Stock Award | 31,246 | - |
| 2026-03-05 | PURI RAJ K | Officer | Stock Award | 39,059 | - |
| 2026-03-02 | BILINSKY IGOR P | Chief Operating Officer | Stock Award | 12,307 | - |
| 2026-03-02 | VOGT FREDERICK G | Chief Executive Officer | Stock Award | 52,087 | - |
| 2026-03-02 | GRAF FINCKENSTEIN FRIEDRICH | Officer | Stock Award | 12,697 | - |
| 2026-03-02 | PURI RAJ K | Officer | Stock Award | 5,470 | - |
| 2026-02-24 | KIRBY DANIEL GORDON | Officer | Stock Award | 120,000 | - |
| 2026-02-10 | KIRBY DANIEL GORDON | Officer | Stock Award | 39,996 | - |
| 2025-12-02 | BILINSKY IGOR P | Chief Operating Officer | Stock Award | 12,305 | - |
| 2025-12-02 | VOGT FREDERICK G | Chief Executive Officer | Stock Award | 52,086 | - |
| 2025-12-02 | GRAF FINCKENSTEIN FRIEDRICH | Officer | Stock Award | 12,695 | - |
| 2025-12-01 | PURI RAJ K | Officer | Stock Award | 5,469 | - |
BILINSKY IGOR P
Chief Operating Officer
2026-03-05
31,246 shares
VOGT FREDERICK G
Chief Executive Officer
2026-03-05
62,493 shares
GRAF FINCKENSTEIN FRIEDRICH
Officer
2026-03-05
31,246 shares
PURI RAJ K
Officer
2026-03-05
39,059 shares
BILINSKY IGOR P
Chief Operating Officer
2026-03-02
12,307 shares
VOGT FREDERICK G
Chief Executive Officer
2026-03-02
52,087 shares
GRAF FINCKENSTEIN FRIEDRICH
Officer
2026-03-02
12,697 shares
PURI RAJ K
Officer
2026-03-02
5,470 shares
KIRBY DANIEL GORDON
Officer
2026-02-24
120,000 shares
KIRBY DANIEL GORDON
Officer
2026-02-10
39,996 shares
BILINSKY IGOR P
Chief Operating Officer
2025-12-02
12,305 shares
VOGT FREDERICK G
Chief Executive Officer
2025-12-02
52,086 shares
GRAF FINCKENSTEIN FRIEDRICH
Officer
2025-12-02
12,695 shares
PURI RAJ K
Officer
2025-12-01
5,469 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
10 analysts
Chardan Capital
2026-04-10
Buy
Buy
UBS
2026-03-05
Neutral
Neutral
Citizens
2026-03-03
Market Perform
Market Outperform
Barclays
2026-02-25
Overweight
Overweight
Citizens
2026-02-25
Market Perform
Market Outperform
Barclays
2025-12-17
Overweight
Overweight
Barclays
2025-11-24
Overweight
Overweight
Chardan Capital
2025-11-06
Buy
Buy
HC Wainwright & Co.
2025-10-29
Buy
Buy
Past News Coverage
Recent headlines mentioning IOVA from our newsroom.
Newest → oldest
No matching news yet.